Bioqual Stock

Bioqual EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Bioqual (BIOQ) as of Jul 27, 2026 is -17.68. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1,710.61 — a change of -98.97% (higher).

EV/EBIT

-17.68

YoY

-98.97%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Bioqual is 2026 -17.68 . EV/EBIT (Enterprise Value to EBIT) of Bioqual was 2025 -1,710.61 . It decreases by -98.97% higher compared to the previous year.

The Bioqual EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
6.23 base
Jan 1, 2019
11.60 base
Jan 1, 2020
13.44 base
Jan 1, 2021
10.87 base
Jan 1, 2022
11.20 base
Jan 1, 2023
51.90 base
Jan 1, 2024
-3,016.32 base
Jan 1, 2025
-18.17 base
YEARPRICE-TO-EBIT
2025 -18.17
2024 -3,016.32
2023 51.90
2022 11.20
2021 10.87
2020 13.44
2019 11.60
2018 6.23
2017 5.32
2016 5.87
2015 4.68
2001 -
2000 -
1999 -
1998 -
1997 -
1996 -
1995 -
1994 -
1993 -
Access this data via the Eulerpool API

Bioqual Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Bioqual's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Bioqual's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Bioqual's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Bioqual grows earnings faster than its peers.

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioqual stock

EV/EBIT (Enterprise Value to EBIT) of Bioqual is -17.68 in 2026.

Access this data via the Eulerpool API

Valuation — Bioqual

All Key Metrics — Bioqual